Regulus Therapeutics Inc. or Regulus (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. MicroRNAs are small naturally occurring RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead have evolved to regulate gene expression. Anti-miR therapeutics inhibit specific microRNA targets. Animal models showed that modulating microRNAs through anti-miRs effectively regulates biological processes and provides therapeutic benefit to cardiac dysfunction, cancer and hepatitis C virus infection. Administration of anti-miR oligonucleotides is possible through local or parenteral injection. The company's lead drug candidate, RG-012, is intended as a treatment for alport syndrome in phase 2 clinical trials. More information...
According to PR-model, regulusrx.com is ranked 2,283,085th in multilingual Wikipedia, in particular this website is ranked 1,254,768th in English Wikipedia.
The website is placed before novatech.co.uk and after smogenbryggan.org in the BestRef global ranking of the most important sources of Wikipedia.
